GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Current Deferred Revenue

Arch Biopartners (TSXV:ARCH) Current Deferred Revenue : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Arch Biopartners's current deferred revenue for the quarter that ended in Dec. 2024 was C$0.00 Mil.

Arch Biopartners Current Deferred Revenue Historical Data

The historical data trend for Arch Biopartners's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Current Deferred Revenue Chart

Arch Biopartners Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.10 0.12

Arch Biopartners Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Dec24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.80 - 0.12 -

Arch Biopartners Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Current Deferred Revenue
Comparable Companies
TSX:MSCL TSX:MDNA XCNQ:GLAB TSXV:COV TSX:SVA TSX:TH NEOE:ONCO TSXV:MIR TSXV:NRX TSXV:SHRX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ACHFF:USA
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Website
https://www.archbiopartners.com
Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.